Literature DB >> 29740495

In vitro assessment of the role of DpC in the treatment of head and neck squamous cell carcinoma.

Ye-Xing Xu1, Man-Li Zeng2, Di Yu1, Jie Ren1, Fen Li1,3, Anyuan Zheng1, Yong-Ping Wang1, Chen Chen1,3, Ze-Zhang Tao1,2,3.   

Abstract

The present study aimed to investigate the antitumor efficacy of di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone (DpC) and di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone (Dp44mT) on head and neck squamous cell carcinoma (HNSCC) cells. The proliferation and apoptosis of HNSCC cells treated with the iron chelators DpC and Dp44mT were detected. The mechanism of DpC-induced apoptosis on HNSCC cells was investigated. The human HNSCC cell lines FaDu, Cal-27 and SCC-9 were cultured in vitro and exposed to gradient concentrations of DpC and Dp44mT. A Cell Counting Kit-8 assay was used to detect the viability of FaDu, Cal-27, SCC-9 cells. Double staining with annexin V and propidium iodide was performed for the detection of the proportion of apoptotic FaDu, Cal-27 and SCC-9 cells following treatment. The nuclear damage to Cal-27 cells that were treated with DpC was detected by Hoechst staining. Finally, western blot analysis was used to detect the expression of proteins associated with the DNA damage pathway in Cal-27 cells that were treated with DpC. The CCK-8 assay showed that treatment with DpC and Dp44mT was able to markedly inhibit the viability of FaDu, Cal-27 and SCC-9 cells in a concentration-dependent manner. In comparison to Dp44mT, treatment with DpC exhibited a more effective inhibitory effect on the viability of HNSCC cells. The proportion of apoptotic cells detected by flow cytometry increased in a dose-dependent manner in all cell lines following DpC and Dp44mT treatment, with the proportion of apoptotic HNSCC cells induced by DpC treatment being significantly higher compared with Dp44mT (P<0.05). The results of Hoechst staining revealed that the nuclei of Cal-27 cells exhibited morphological changes in response to DpC treatment, including karyopyknosis and nuclear fragmentation. The expression of DNA damage-associated proteins, including phosphorylated (p)-serine-protein kinase ATM, p-serine/threonine-protein kinase Chk1 (p-Chk-1), p-serine/threonine-protein kinase ATR (p-ATR), p-Chk-2, poly (ADP-ribose) polymerase, p-histone H2AX, breast cancer type 1 susceptibility protein, p-tumor protein P53, increased with increasing concentration of DpC in Cal-27 cells. Treatment with DpC and Dp44mT markedly inhibited cell viability and increased the apoptotic rates in human HNSCC cells in a concentration-dependent manner. DpC exhibited a stronger antitumor effect compared with Dp44mT, potentially inducing the apoptosis of HNSCC cells via the upregulation of DNA damage repair-associated proteins.

Entities:  

Keywords:  DNA damage; apoptosis; di-2-pyridylketone-4,4,-dimethyl-3-thiosemicarbazone; di-2-pyridylketone-4-cyclohexyl-4-methyl-3-thiosemicarbazone; head and neck squamous cell carcinoma; proliferation

Year:  2018        PMID: 29740495      PMCID: PMC5934731          DOI: 10.3892/ol.2018.8279

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  38 in total

1.  Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes.

Authors:  David B Lovejoy; Patric J Jansson; Ulf T Brunk; Jacky Wong; Prem Ponka; Des R Richardson
Journal:  Cancer Res       Date:  2011-07-12       Impact factor: 12.701

2.  The chemotherapy of experimental tuberculosis. II. Thiosemicarbazones and analogues in experimental tuberculosis in the mouse.

Authors:  D HAMRE; J BERNSTEIN; R DONOVICK
Journal:  J Bacteriol       Date:  1950-05       Impact factor: 3.490

3.  A novel antimycobacterial compound acts as an intracellular iron chelator.

Authors:  Marte S Dragset; Giovanna Poce; Salvatore Alfonso; Teresita Padilla-Benavides; Thomas R Ioerger; Takushi Kaneko; James C Sacchettini; Mariangela Biava; Tanya Parish; José M Argüello; Magnus Steigedal; Eric J Rubin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

4.  Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy.

Authors:  Y Yu; Y Suryo Rahmanto; D R Richardson
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

5.  Spectrophotometric, voltammetric and cytotoxicity studies of 2-hydroxy-5-methoxyacetophenone thiosemicarbazone and its N(4)-substituted derivatives: a combined experimental-computational study.

Authors:  Emine Guler Akgemci; Ahmet Ozgur Saf; Halil Ugur Tasdemir; Ercan Türkkan; Haluk Bingol; Suna Ozbas Turan; Mustafa Akkiprik
Journal:  Spectrochim Acta A Mol Biomol Spectrosc       Date:  2014-09-30       Impact factor: 4.098

Review 6.  Iron and colorectal cancer: evidence from in vitro and animal studies.

Authors:  Hari Padmanabhan; Matthew J Brookes; Tariq Iqbal
Journal:  Nutr Rev       Date:  2015-04-07       Impact factor: 7.110

7.  Design and synthesis of novel 5,6-disubstituted pyridine-2,3-dione-3-thiosemicarbazone derivatives as potential anticancer agents.

Authors:  Wenlin Xie; Shimin Xie; Ying Zhou; Xufu Tang; Jian Liu; Wenqian Yang; Minghua Qiu
Journal:  Eur J Med Chem       Date:  2014-05-04       Impact factor: 6.514

8.  A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.

Authors:  Brigette Ma; Boon Cher Goh; Eng Huat Tan; Kwok Chi Lam; Ross Soo; Swan Swan Leong; Ling Zhi Wang; Frankie Mo; Anthony T C Chan; Benny Zee; Tony Mok
Journal:  Invest New Drugs       Date:  2007-09-12       Impact factor: 3.850

9.  Glucose Modulation Induces Lysosome Formation and Increases Lysosomotropic Drug Sequestration via the P-Glycoprotein Drug Transporter.

Authors:  Nicole A Seebacher; Darius J R Lane; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2015-11-24       Impact factor: 5.157

10.  Antibacterial, antifungal and in vitro antileukaemia activity of metal complexes with thiosemicarbazones.

Authors:  Elena Pahontu; Felicia Julea; Tudor Rosu; Victor Purcarea; Yurie Chumakov; Petru Petrenco; Aurelian Gulea
Journal:  J Cell Mol Med       Date:  2015-02-24       Impact factor: 5.310

View more
  8 in total

1.  The metastasis suppressor NDRG1 down-regulates the epidermal growth factor receptor via a lysosomal mechanism by up-regulating mitogen-inducible gene 6.

Authors:  Sharleen V Menezes; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

2.  Thiosemicarbazones suppress expression of the c-Met oncogene by mechanisms involving lysosomal degradation and intracellular shedding.

Authors:  Kyung Chan Park; Bekesho Geleta; Lionel Yi Wen Leck; Jasmina Paluncic; Shannon Chiang; Patric J Jansson; Zaklina Kovacevic; Des R Richardson
Journal:  J Biol Chem       Date:  2019-11-19       Impact factor: 5.157

3.  E6AP Promotes a Metastatic Phenotype in Prostate Cancer.

Authors:  Cristina Gamell; Ivona Bandilovska; Twishi Gulati; Arielle Kogan; Syer Choon Lim; Zaklina Kovacevic; Elena A Takano; Clelia Timpone; Arjelle D Agupitan; Cassandra Litchfield; Giovanni Blandino; Lisa G Horvath; Stephen B Fox; Scott G Williams; Andrea Russo; Enzo Gallo; Piotr J Paul; Catherine Mitchell; Shahneen Sandhu; Simon P Keam; Sue Haupt; Des R Richardson; Ygal Haupt
Journal:  iScience       Date:  2019-11-02

4.  Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors against NDM-1 producing clinical isolates.

Authors:  Bing Zhao; Xinhui Zhang; Tingting Yu; Ying Liu; Xiaoling Zhang; Yongfang Yao; Xuejian Feng; Hongmin Liu; Dequan Yu; Liying Ma; Shangshang Qin
Journal:  Acta Pharm Sin B       Date:  2020-07-16       Impact factor: 11.413

5.  Design and Synthesis of Novel Betulin Derivatives Containing Thio-/Semicarbazone Moieties as Apoptotic Inducers through Mitochindria-Related Pathways.

Authors:  Jiafeng Wang; Jiale Wu; Yinglong Han; Jie Zhang; Yu Lin; Haijun Wang; Jing Wang; Jicheng Liu; Ming Bu
Journal:  Molecules       Date:  2021-10-21       Impact factor: 4.411

6.  Deferoxamine Inhibits Acute Lymphoblastic Leukemia Progression through Repression of ROS/HIF-1α, Wnt/β-Catenin, and p38MAPK/ERK Pathways.

Authors:  Hongliang You; Dao Wang; Linlin Wei; Jiao Chen; Huanhuan Li; Yufeng Liu
Journal:  J Oncol       Date:  2022-02-21       Impact factor: 4.375

7.  Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells.

Authors:  Maria Krchniakova; Silvia Paukovcekova; Petr Chlapek; Jakub Neradil; Jan Skoda; Renata Veselska
Journal:  Front Pharmacol       Date:  2022-09-07       Impact factor: 5.988

8.  Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism.

Authors:  Yujing Yang; Yanli Xu; Ailing Su; Dan Yang; Xuezhong Zhang
Journal:  Med Sci Monit       Date:  2018-09-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.